Fabry Disease - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 24, 2019--The “Fabry Disease - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Fabry Disease - Pipeline Insight, 2019 offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fabry Disease development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Fabry Disease pipeline products by developmental stage, product type, molecule type, and administration route.
Companies FeaturedActelion Ltd. Amicus Therapeutics Inc. Genzyme Corp. Greenovation Biotech GmbH JCR Pharmaceuticals Co. Ltd. Neuraltus Pharmaceuticals Inc. Pharming Group N.V. Protalix BioTherapeutics Inc. Sangamo Therapeutics Inc. Shire PLC
1. Report Introduction
2. Fabry Disease Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Fabry Disease
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name: Company NameProduct Description Research and Development Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name: Company NameProduct Description Research and Development Product Development Activities
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name: Company NameProduct Description Research and Development Product Development Activities
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/g4pl4h/fabry_disease?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190124005695/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/24/2019 01:25 PM/DISC: 01/24/2019 01:25 PM